News | June 16, 2008

Medtronic’s New Left-Heart CRT Lead Gets FDA Clearance

June 17, 2008 - The FDA has cleared Medtronic Attain StarFix OTW (over-the-wire) lead (Model 4195), an active fixation left-heart lead for cardiac resynchronization therapy (CRT).

The Attain StarFix lead, according to the manufacturer, overall, including the acute dislodgements at one day post-implant, has had a low 0.7 percent dislodgement rate. These dislodgement rates are supported by one of the industry’s largest and longest-running left-heart lead clinical studies involving 385 implants followed for up to four years.

The Medtronic Attain StarFix steroid-eluting unipolar lead has a 5-French diameter and is available in 78, 88 and 103 cm. lengths. The Attain StarFix's design includes three soft, polyurethane lobes near the lead tip that, when expanded, enable stable lead placement in the target location. The soft, pliable lobes, which can be deployed to up to a 24-French diameter - about one quarter inch - can reportedly be relaxed multiple times to allow for acute repositioning of the lead as necessary. Once deployed, the electrode is securely fixed in place, reducing the potential for dislodgement.

The Attain StarFix lead is designed for achieving successful placement and stability of the left-heart lead in heart failure patients receiving a CRT device. A patient’s vein size or configuration can make it difficult to secure a left-heart lead in the optimal location. Therefore, stable fixation of the left-heart lead is critical to a successful CRT implantation. Dislodgement of the left heart lead may require additional surgeries, which could increase the risk of infection.

“With the Attain StarFix’s unique active fixation mechanism, physicians have a left-heart lead that can be safely placed in a wide variety of veins regardless of location and diameter,” said Stuart Adler, M.D., clinical cardiac electrophysiologist, St. Paul Heart Clinic, St. Paul, Minn. “This lead helps to ensure successful placement of CRT therapy in even the most difficult cases, which ultimately results in better management of my patients’ cardiac disease.”

The Attain StarFix lead, which will be commercially available nationwide in late summer 2008, is designed to complement the Attain Model 4193 and Model 4194 over-the-wire leads. The Attain catheters along with the Attain Hybrid Guide Wires are used to deliver leads for precise placement in a wide variety of coronary anatomies. It can be used with any Medtronic CRT-defibrillator (CRT-D), including those within the company's new Vision 3D(tm) portfolio. The new Vision 3D wireless ICD and CRT-D portfolio offers unparalleled depth and breadth of unique clinical options that are built on our industry leading pacing and ICD exclusives.

For more information: www.medtronic.com

Related Content

Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD
Technology | Cardiac Resynchronization Therapy Devices (CRT)| January 03, 2018
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Videos | Cardiac Resynchronization Therapy Devices (CRT)| May 23, 2017
This video, provided by ERB, demonstrates the function and implantation of the WiSE CRT (Wireless Stimulation Endocar
Biotronik Announces FDA Approval of MultiPole Pacing
Technology | Cardiac Resynchronization Therapy Devices (CRT)| May 11, 2017
May 11, 2017 — Biotronik announced U.S.
Biotronik Launches First FDA-Approved CRM Devices with MRI AutoDetect Technology
Technology | Cardiac Resynchronization Therapy Devices (CRT)| May 10, 2017
Biotronik announced the availability of the first U.S. Food and Drug Administration (FDA)-approved cardiac rhythm...
NICE Recommends Boston Scientific CRT-Ds With EnduraLife Battery Technology for Heart Failure Treatment
News | Cardiac Resynchronization Therapy Devices (CRT)| April 14, 2017
The National Institute for Health and Care Excellence (NICE) recently issued medical technology guidance recommending...
Biotronik, Edora series, pacemakers, CRT-Ps
Technology | Cardiac Resynchronization Therapy Devices (CRT)| March 23, 2017
March 23, 2017 — Biotronik announced the European launch of the Edora series, its smallest series of...
Overlay Init